EUVIMEDEUVIMED entdecken
Crossref

EVI2B May be a Novel Prognostic Marker for Lung Adenocarcinoma

Yin Fu iD, Junming He iD, Jian Chen iD, Jiangwei Hu iD, Wei Guan iD, Guoliang Lou iD

Biomarkers in Medicine · 2023

DOI: 10.2217/bmm-2023-0195 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomarkers in Medicine, 2023. Verfasst von Yin Fu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiothoracic Surgery, Yiwu Central Hospital, Yiwu City, Zhejiang Province, 322000, China. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Lung Neoplasms, Membrane Glycoproteins. Die Arbeit nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study intended to unravel the relationship of EVI2B expression with lung adenocarcinoma (LUAD).

Methods

TIMER1.0, Gene Expression Profiling Interactive Analysis and Human Protein Atlas databases, as well as the University of Alabama at Birmingham Cancer website, were used to analyze the expression of EVI2B and its relationship with clinical features. The relationship between survival curve analysis and prognosis was analyzed. The role of EVI2B in LUAD was verified by wet experiments.

Results

EVI2B was markedly downregulated in LUAD. There was a relationship between the expression of EVI2B and clinical features. Low EVI2B level was substantially implicated in low survival in LUAD. EVI2B overexpression constrained LUAD cell viability, migration and invasion.

Conclusion

EVI2B was related to prognosis and immune microenvironment in LUAD, suggesting that EVI2B may be a novel prognostic marker for LUAD. Lung adenocarcinoma (LUAD) is a type of cancer. It causes many deaths. However, there is no good treatment for it yet. Scientists found a gene called EVI2B. EVI2B can help show how bad the cancer is. EVI2B is at a low level in LUAD. When it is high, patients have a better chance of surviving. EVI2B is linked to the immune system fighting cancer. It can be used to check the progression of LUAD. EVI2B may help with new treatments in the future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adenocarcinoma of LungLung NeoplasmsMembrane GlycoproteinsHumansCell SurvivalDatabases, FactualPrognosisTumor Microenvironment

Stichwörter der Autor:innen

EVI2BTCGAbiomarkerimmune infiltrationlung adenocarcinoma

Substanzen

EVI2B protein, humanMembrane Glycoproteins

Autor:innen und Institutionen

  • Department of Cardiothoracic Surgery, Yiwu Central Hospital, Yiwu City, Zhejiang Province, 322000, China.

ORCID-Profile: Yin Fu, Junming He, Jian Chen, Jiangwei Hu, Wei Guan, Guoliang Lou

Zitieren

APA

Fu, Y., He, J., Chen, J., Hu, J., Guan, W., & Lou, G. (2023). EVI2B May be a Novel Prognostic Marker for Lung Adenocarcinoma. Biomarkers in Medicine. https://doi.org/10.2217/bmm-2023-0195

Vancouver

Fu Y, He J, Chen J, Hu J, Guan W, Lou G. EVI2B May be a Novel Prognostic Marker for Lung Adenocarcinoma. Biomarkers in Medicine. 2023. doi:10.2217/bmm-2023-0195

BibTeX
@article{Fu2023,
  author = {Fu, Yin and He, Junming and Chen, Jian and Hu, Jiangwei and Guan, Wei and Lou, Guoliang},
  title = {EVI2B May be a Novel Prognostic Marker for Lung Adenocarcinoma},
  journal = {Biomarkers in Medicine},
  year = {2023},
  doi = {10.2217/bmm-2023-0195}
}
Kostenlos starten →